Polaryx TherapeuticsPLYX
13F holders, Q2 2026 (June 30)13holders −1
4new positions
5sold out
$2.66avg. 13F price*
At the end of Q2 2026, 13 institutions reported holding Polaryx Therapeutics Inc. (PLYX) in their 13F filings, down 1 from Q1 2026. 4 opened new positions and 5 sold out. The largest holders were Vanguard Capital Management LLC ($4.4M), Geode Capital Management, LLC ($455K) and Vanguard Fiduciary Trust Co. ($279K).
- Company
- Polaryx Therapeutics Inc.
- CUSIP
- 73110F100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $323K |
| Exits | 5 | $1.4M |
All 13F filers, Q1 2026 → Q2 2026: 123,513 shares bought and 197,550 shares sold, net −74,037 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Vanguard Capital Management LLC | 0.00% | Reduce -0.0% | 1,657,872 | $4.4M |
| Geode Capital Management, LLC | 0.00% | Add +0.2% | 170,998 | $455K |
| Vanguard Fiduciary Trust Co. | 0.00% | Add +0.5% | 105,072 | $279K |
| HRT Financial LP | 0.00% | New | 82,094 | $218K |
| State Street Corp. | 0.00% | No change | 58,104 | $155K |
| BlackRock, Inc. | 0.00% | No change | 41,012 | $109K |
| Jane Street Group, LLC | 0.00% | New | 31,441 | $84K |
| Northern Trust Corp. | 0.00% | No change | 27,987 | $74K |
| Allworth Financial LP | 0.00% | New | 7,727 | $21K |
| Vanguard Global Advisers, LLC | 0.00% | No change | 6,318 | $17K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +68.6% | 3,002 | $8K |
| UBS Group AG | 0.00% | Reduce -90.5% | 1,283 | $3K |
| Fortitude Family Office, LLC | 0.00% | New | 189 | $503 |
"% of holder's portfolio" is PLYX's weight in each manager's 13F, not the share of Polaryx Therapeutics Inc. the manager owns.